New Haven County

Connecticut accounting firms are rapidly adopting artificial intelligence to handle routine tasks like data entry and financial analysis, with industry surveys showing 21% already using the technology and another 53% planning or considering adoption amid pressure to deliver faster insights.

Brook + Whittle, a Guilford-based manufacturer of labels and flexible packaging, has appointed Carl Will as its new CEO.

A developer is proposing a new, seven-story apartment building on New Haven’s Orange Street, providing 190 units...

New Haven-based Trevi Therapeutics has raised more than $250 million to develop Haduvio, the only drug in development for chronic cough, with the company preparing Phase 3 trials targeting patients with idiopathic pulmonary fibrosis who cough thousands of times daily.

West Hartford developer Matthew Haubrich is proposing a rare 19-house subdivision in East Hartford priced between $400,000 and $500,000, aiming to fill a widening gap as entry-level single-family homes become increasingly scarce in Connecticut's housing market.

The current structure was built in 1972, and the developer says it has reached the end of its useful life and renovation is not feasible.

New Haven-based BioXcel Therapeutics has approved retention and milestone bonus agreements for senior executives following the company’s recent regulatory push to expand the use of its lead drug, IGALMI.

A hearing has been set for public comment on Encompass Health Corp.’s proposal to build a rehabilitation hospital in Branford.

Four Fairfield County towns and two regional planning groups filed an appeal on Wednesday with the state’s Appellate Court, challenging a Superior Court judge’s decision to remand Eversource Energy’s proposed $2.4 billion sale of Aquarion Water Co. back to state regulators.

Veradermics Inc., the New Haven drug developer working on an oral treatment for hair loss, raised $256.3 million from its initial public offering on Wednesday.